Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.94 Insider Own0.10% Shs Outstand20.88M Perf Week-7.36%
Market Cap81.43M Forward P/E- EPS next Y-2.30 Insider Trans0.00% Shs Float20.73M Perf Month6.27%
Income-41.10M PEG- EPS next Q-0.45 Inst Own38.60% Short Float1.46% Perf Quarter379.53%
Sales2.50M P/S32.57 EPS this Y29.80% Inst Trans-5.40% Short Ratio2.32 Perf Half Y584.33%
Book/sh-0.98 P/B- EPS next Y12.50% ROA-111.90% Target Price6.00 Perf Year355.93%
Cash/sh1.16 P/C3.36 EPS next 5Y- ROE- 52W Range0.44 - 5.00 Perf YTD334.54%
Dividend- P/FCF- EPS past 5Y12.70% ROI-210.20% 52W High-22.00% Beta1.92
Dividend %- Quick Ratio2.40 Sales past 5Y147.30% Gross Margin- 52W Low790.41% ATR0.16
Employees38 Current Ratio2.40 Sales Q/Q-14.30% Oper. Margin- RSI (14)39.26 Volatility3.32% 4.08%
OptionableYes Debt/Eq- EPS Q/Q-9.60% Profit Margin- Rel Volume0.11 Prev Close3.96
ShortableYes LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume131.02K Price3.90
Recom2.00 SMA20-2.88% SMA50-5.81% SMA200133.48% Volume14,105 Change-1.52%
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Nov-10-16 01:04PM  SUNESIS PHARMACEUTICALS INC Financials
Nov-03-16 11:10AM  Sunesis reports 3Q loss
11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:25AM  Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting GlobeNewswire
07:07AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Nov-02-16 07:59AM  Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake at Insider Monkey
Oct-27-16 07:00AM  Sunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Oct-24-16 04:05PM  Sunesis Announces Closing of Public Offerings and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-19-16 04:11PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to
09:07AM  Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More at Insider Monkey
09:02AM  Sunesis Announces Pricing of $25 Million Offering of Securities GlobeNewswire
Oct-18-16 04:01PM  Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire
07:00AM  Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference GlobeNewswire
Oct-14-16 10:03AM  Sunesis Submits Response to Questions on Leukemia Drug
Oct-13-16 04:05PM  Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin GlobeNewswire
Sep-27-16 01:11PM  What it Costs Apple to Make an iPhone 7: $219 Parts, $5 Labor at Investopedia
Sep-26-16 04:13PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Sep-12-16 05:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Sunesis Pharmaceuticals, Inc. Preliminary Results From the Oral Non-Covalent BTK-inhibitor SNS-062 Call scheduled for 8:00 am ET today
06:00AM  Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 GlobeNewswire
Sep-09-16 11:24AM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : September 9, 2016 +8.99%
Sep-07-16 05:03PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina -10.18%
02:00PM  Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split GlobeNewswire
Sep-01-16 07:00AM  Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematologys 2nd International Conference o GlobeNewswire
Aug-31-16 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-16 07:00AM  Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin GlobeNewswire +12.66%
Aug-18-16 06:53PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : August 18, 2016 +6.49%
08:15AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 23.1%
Aug-04-16 03:17PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : August 4, 2016
Aug-03-16 01:48PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Aug-01-16 12:36PM  Edited Transcript of SNSS earnings conference call or presentation 29-Jul-16 3:00pm GMT +7.56%
Jul-29-16 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today +28.44%
09:18AM  Sunesis reports 2Q loss
08:15AM  Sunesis Pharma upgraded by Wells Fargo
07:32AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q2 2016 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Jul-21-16 07:00AM  Sunesis to Host Conference Call on July 29th to Discuss Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Jul-05-16 07:00AM  Sunesis Pharmaceuticals to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference GlobeNewswire
Jun-21-16 08:45AM  Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%
Jun-17-16 11:00AM  7 Biotech Stocks that are Buys Right Now
Jun-13-16 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting GlobeNewswire
Jun-09-16 09:42AM  Most Popular Healthcare Penny Stocks Among Hedge Funds at Insider Monkey -5.87%
Jun-08-16 04:14PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-06-16 05:43PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : June 6, 2016 -5.02%
09:12AM  Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting GlobeNewswire
Jun-01-16 07:00AM  Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development GlobeNewswire
May-27-16 06:08AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
May-25-16 09:00AM  Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June GlobeNewswire
May-19-16 07:58PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 19, 2016
07:28AM  Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association GlobeNewswire
May-18-16 01:56PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2016 By the Numbers
07:00AM  Sunesis to Present at the 2016 UBS Global Healthcare Conference GlobeNewswire
May-11-16 04:14PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -5.48%
May-09-16 04:40PM  SUNESIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
May-05-16 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:40AM  Sunesis reports 1Q loss
07:07AM  Q1 2016 Sunesis Pharmaceuticals Inc Earnings Release - Time Not Supplied
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Apr-28-16 07:00AM  Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights GlobeNewswire -5.28%
Apr-15-16 04:12PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-06-16 04:14PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
03:20PM  Edited Transcript of SNSS earnings conference call or presentation 10-Mar-16 4:00pm GMT
Apr-05-16 07:00AM  Sunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference GlobeNewswire
Apr-01-16 08:17AM  Sunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan GlobeNewswire
Mar-29-16 10:53AM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : March 29, 2016
Mar-28-16 04:13PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:19AM  Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors at noodls
07:00AM  Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors GlobeNewswire
Mar-24-16 07:23AM  Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML at noodls -10.08%
07:00AM  Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML GlobeNewswire
Mar-23-16 07:32AM  Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at noodls
07:00AM  Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 GlobeNewswire
Mar-18-16 01:21PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : March 18, 2016 +9.20%
Mar-17-16 02:34PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2015 By the Numbers
Mar-14-16 06:12AM  SUNESIS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report -9.67%
Mar-10-16 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today -6.00%
08:59AM  Sunesis reports 4Q loss
07:07AM  Q4 2015 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
07:02AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights GlobeNewswire
Mar-03-16 07:00AM  Sunesis to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights GlobeNewswire
Mar-01-16 07:00AM  Sunesis Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire -5.87%
Feb-19-16 07:00AM  Sunesis Pharmaceuticals Announces Promotion of Deborah A. Thomas, Ph.D., to Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development GlobeNewswire
Feb-18-16 06:04AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-08-16 12:18PM  Edited Transcript of SNSS earnings conference call or presentation 5-Nov-15 4:00pm GMT
Jan-04-16 07:00AM  Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML GlobeNewswire
Dec-24-15 07:33AM  Will Sunesis Pharmaceuticals (SNSS) Continue to Surge Higher?
Dec-21-15 04:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Sunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriters Over-Allotment Option GlobeNewswire
Dec-17-15 10:58AM  Sunesis Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-16-15 05:01PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to
08:20AM  Sunesis Announces Pricing of $25 Million Offering of Securities GlobeNewswire
Dec-08-15 07:00AM  Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe GlobeNewswire
Dec-07-15 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial in AML at ASH Annual Meeting GlobeNewswire -6.59%
Dec-06-15 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase 1/2 Trial of Vosaroxin in MDS and VALOR Analysis of Baseline Safety Predictors at ASH Annual Meeting GlobeNewswire
Dec-03-15 07:00AM  Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia GlobeNewswire -6.02%
Dec-01-15 07:00AM  Sunesis Pharmaceuticals Announces First Patient Treated in Indiana University Pilot Study of Vosaroxin and Cytarabine in Adults Age 60 Years and Older With Previously Untreated AML GlobeNewswire -6.11%
Nov-30-15 07:00AM  Sunesis Pharmaceuticals Announces European Patent Covering Vosaroxin Combination Use in AML and Other Hematologic Malignancies GlobeNewswire +8.42%
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase; The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.DirectorMay 26Buy0.479,5004,45562,005May 27 05:26 PM
Parker Geoffrey M.DirectorMay 25Buy0.4922,50510,93352,505May 26 05:04 PM
Parker Geoffrey M.DirectorMay 24Buy0.4630,00013,88130,000May 26 05:04 PM
Misfeldt DaytonDirectorDec 21Buy0.841,750,0001,470,0007,234,441Dec 21 09:31 PM